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Background: Species identification and antifungal susceptibility tests were carried out on 212 Candida isolates
obtained from bloodstream infections, urinary tract infections and dialysis-associated peritonitis, from cases
attended at a Brazilian public tertiary hospital from January 1998 to January 2005.
Findings: Candida albicans represented 33% of the isolates, Candida parapsilosis 31.1%, Candida tropicalis 17.9%,
Candida glabrata 11.8%, and others species 6.2%. In blood culture, C. parapsilosis was the most frequently
encountered species (48%). The resistance levels to the antifungal azoles were relatively low for the several species,
except for C. tropicalis and C. glabrata. Amphotericin B resistance was observed in 1 isolate of C. parapsilosis.
Conclusions: The species distribution and antifungal susceptibility herein observed presented several
epidemiological features common to other tertiary hospitals in Latin American countries. It also exhibited some
peculiarity, such as a very high frequency of C. parapsilosis both in bloodstream infections and dialysis-associated
peritonitis. C. albicans also occurred in an important number of case infections, in all evaluated clinical sources. C.
glabrata presented a high proportion of resistant isolates. The data emphasize the necessity to carry out the
correct species identification accompanied by the susceptibility tests in all tertiary hospitals.
Findings
Infections caused by opportunistic pathogens, such as
yeasts, are becoming important causes of morbidity and
mortality in many patients, because of alterations in the
immune system and invasive hospital procedures [1].
Candidemia is commonly associated with high morbidity
and mortality resulting in significant increases in the
length of patients’ hospitalization and in healthcare
costs [2].
In the past two decades, nosocomial yeast infections
have increased significantly worldwide [3]. In the United
States, yeast infection ranks as the 4th most common
cause of nosocomial bloodstream infection (BSI) [3]. In
Brazil, Candida albicans, Candida tropicalis and Can-
dida parapsilosis are the most common species isolated
from BSI in several medical centers [2,4,5]. There has
been an important shift in the species causing
nosocomial candidemia, with the emergence of non-
albicans species, particularly those more resistant to
antifungal drugs [6,7]. Although studies demonstrate
that antifungal resistance is relatively rare [2,4,8], anti-
fungal drugs have been used intensively either to control
such infections or as prophylactic in long-term treat-
ments, creating serious worries that might select for
drug resistances, thus greatly harming infection control
[9,10]. Candida species have various degrees of suscept-
ibility to the frequently used antifungal drugs. For exam-
ple, while Candida krusei is intrinsically resistant to
fluconazole, Candida glabrata is less susceptible or has
higher MICs than other Candida species [10], which
makes the correct species identifications and susceptibil-
ity tests pressing necessities.
In the present work, we present data on species fre-
quency and antifungal susceptibility of Candida isolates
obtained in a Brazilian public tertiary hospital.
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Species identification
Table 1 demonstrates the species distribution of Can-
dida isolates. In a total of 212 yeast cultures, 70 (33%)
were isolates of C. albicans, 66 (31.8%) C. parapsilosis,
38 (17.9%) C. tropicalis,2 5( 1 1 . 8 % )C. glabrata,1 0
(4.7%) C. guilliermondii,2( 0 . 9 % )C. lusitaniae and 1
(0.5%) C. pelliculosa. With regard to clinical materials,
C. parapsilosis was the species most commonly isolated
from bloodstream infections (BSI) and also from perito-
neal fluid (PF), while C. albicans presented a homoge-
neous distribution among the three sources, BSI, PF and
urinary tract infections (UTI). C. tropicalis and C. glab-
rata were observed mainly in UTI isolates.
Susceptibility tests
Susceptibility tests for fluconazole, itraconazole and
amphotericin B were performed on 212 isolates of Can-
dida species. Table 2 summarizes the MIC ranges that
delimit inhibition of isolates at proportions of 50 and
90%, determined by visual inspection, after 48 h incuba-
tion. Among all evaluated isolates, including C. glabrata,
31(14.6%) were resistant to fluconazole, 43 (20.3%) to
itraconazole and 1(0.5%) to amphotericin B. When
excluding this species the resistant isolates decrease to
14 (7.8%) and 21 (11.2%) for fluconazole and itracona-
zole, respectively.
Fluconazole exhibited the greatest activity against C.
albicans with resistance observed in 5 (7.1%) isolates.
Seven (18.4%) C. tropicalis,1 ( 1 . 5 % )C. parapsilosis,1 7
(68%) C. glabrata and 1 (10%) C. guilliermondii isolates
were resistant to fluconazole. Resistance to itraconazole
was found in 8 (10%) C. albicans,2 2( 8 8 % )C. glabrata,
2( 3 % )C. parapsilosis, 10 (21.1%) C. tropicalis and 1
(10%) C. guilliermondii isolates. One C. parapsilosis iso-
late was amphotericin B-resistant. Isolates of C. lusita-
niae and C. pelliculosa were susceptible to amphotericin
B and to the azoles.
The MIC for fluconazole, itraconazole and amphoteri-
cin B of the QC strains ranged, respectively, from 1-4
μg/mL, 0.12-0.5 μg/mL and 0.5-1 μg/mL, for Candida
parapsilosis ATCC 22019, and from 16-128 μg/mL,
0.25-1 μg/mL and 1-4 μg/mL for Candida krusei ATCC
6258.
Discussion
The epidemiology of Candida infections has been exten-
sively studied in North America and Europe [11], where
large surveillance programs exist. In Latin America,
these data are limited [2], with some regional studies in
a few medical centers [4,5]. Colombo et al. [2] carried
out the largest multicenter study in eleven medical cen-
ters of nine Brazilian cities; however, our hospital was
n o ti n c l u d e di nt h e i rs t u d y ,a n dt h ed a t as h o w nh e r e i n
presented some peculiar differences both in the species
frequency and in the susceptibility profile. The Botucatu
Clinical Hospital is a regional state medical center that
characteristically attends to a high proportion of patients
from small communities and rural areas, with low access
to medical assistance and low income, who are mainly
in critical condition or in need of some advanced medi-
cal procedures, such as dialysis or chemotherapy. Con-
sistent with several previous studies [2,4,5], the
frequency of non-albicans species herein observed was
greater than C. albicans. C. parapsilosis was the species
most often isolated from BSI and PF, whose frequencies
(43 and 40%) were higher than those observed in the
previous Brazilian multicenter studies (7-40% in BSI)
[2,4,5]. A peculiar species distribution was found in rela-
tion to the clinical sources. While in BSI and PF C.
parapsilosis appears as the leading species, followed by
C. albicans and C. tropicalis,i nU T I ,C. albicans occurs
more frequently, followed by C.tropicalis and C. glab-
rata. Our findings confirm other studies that indicate C.
parapsilosis as one of the most important species caus-
ing candidemia [2-8]. At the same time, the data also
indicate that C. glabrata occurs less frequently, in sub-
stantial contrast to temperate countries of North Amer-
ica and Europe [11]. The predominance of C.
parapsilosis in the peritoneal fluid under our casuistry
also comes as no surprise, considering that this species
appears to be common mainly in Latin America, and in
other countries in patients receiving peritoneal dialysis
[12,13]. The reasons why C. parapsilosis occurs more
frequently in Latin American countries is not completely
understood. C. parapsilosis is considered a commensal
of human skin since it has been isolated from the hands
of health workers [14], who have been identified as the
major vectors in the infection acquisition [15]. At the
same time, other local epidemiological factors also may
make important contributions to the high frequency of
C. parapsilosis in BSI and PF, such as a high proportion
Table 1 Distribution frequency of Candida species
obtained from different clinical materials at the Brazilian
Tertiary Hospital (Clinical Hospital of the UNESP School
of Medicine, Botucatu, São Paulo State).
Species BSI UTI PF Total
% (n) % (n) % (n) % (n)
C. albicans 32.4 (33) 34.1 (29) 32.0 (8) 33.0 (70)
C. glabrata 4.9 (5) 23.5 (20) - 11.8 (25)
C. guilliermondii 6.9 (7) 1.2 (1) 8.0 (2) 4.7 (10)
C. lusitaniae 2.0 (2) - - 0.9 (2)
C. parapsilosis 48.0 (49) 8.2 (7) 40.0 (10) 31.1 (66)
C. pelliculosa 1.0 (1) - - 0.5 (1)
C. tropicalis 4.9 (5) 32.9 (28) 20.0 (5) 17.9 (38)
Total 102 85 25 212
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[16], as well as the intense use of vascular catheters, par-
enteral nutrition and peritoneal dialysis procedures [17].
The isolation of C. pelliculosa,t h ea s e x u a lf o r mo f
Pichia anomala,a n dC. lusitaniae, both rarely causing
BSI, was found in other medical reports from Brazil
[2,18] and other countries [19,20]. C. guilliermondii, also
considered a normal component of human skin and
mucosal flora and less common in the northern hemi-
sphere, has been more frequently isolated in Latin
America and presented reduced susceptibility to fluco-
nazole [21,11,2].
In the present study, most of the isolates were suscep-
tible to the antifungal drugs tested. Resistance to fluco-
nazole and itraconazole was observed relatively high,
mainly in isolates of C. glabrata, C. tropicalis and C.
albicans. Similar to other studies, the percentage of iso-
lates resistant to fluconazole was smaller than to itraco-
nazole [22,23]. As expected, high secondary resistance
rates were observed in C. glabrata to fluconazole (68%)
and itraconazole (88%); this resistance to multiple azoles
has been explained by an upregulation of CDR genes
that encode the CDR efflux pumps [24]. Herein one of
nine isolates of C. guilliermondii presented resistance to
the both azole drugs, and high levels of resistance in C.
guilliermondii has been observed worldwide [25]. The
fact that resistance to amphotericin B was observed in
one isolate of C. parapsilosis is controversial since most
studies report a lack of amphotericin B resistance in
Candida species [2,20,26], while other studies also
found resistance to this drug in C. parapsilosis [4,27].
Amphotericin B is used most commonly in several Bra-
zilian public tertiary hospitals in the treatment of sys-
temic mycosis, in which the patients remain hospitalized
for long periods of treatments, as in our hospital for
paracoccidiodomycosis [28]. The possible effect of this
drug against selectively resistant Candida species should
not be excluded and merits proper evaluation.
In conclusion, the species distribution and antifungal
susceptibility observed herein present several epidemio-
logical features common to those observed in other ter-
tiary hospitals in various Latin American countries,
Table 2 In vitro activity of antifungal agents against Candida spp. isolates from different clinical materials at the
Brazilian Tertiary Hospital (Clinical Hospital of the UNESP School of Medicine, Botucatu, São Paulo State), from 1998
to 2005.
Isolates (n) Drugs





a 0.5 1 2 4 8 16 >16
c 32 64 >64
b
C. albicans (70) FLU 5.7 30.0 40.0 65.7 74.3 80.0 84.3 92.9 100
ITR 57.1 71.4 84.3 87.1 88.6 88.6 90.0 90.0 90.0 90.0 100
AMB 21.0 64.0 100
C. glabrata (25) FLU 4.0 16.0 32.0 92.0 100
ITR 4.0 4.0 8.0 12.0 32.0 48.0 56.0 60.0 76.0 100
AMB 16.0 100
C. guilliermondii (10) FLU 30.0 30.0 80.0 90.0 90.0 90.0 100,0
ITR 20.0 50.0 60.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 100
AMB 10.0 30.0 100
C. parapsilosis (66) FLU 1.5 3.0 10.6 33.3 69.7 89.4 98.5 98.5 98.5 98.5 100
ITR 69.7 90.9 97.0 97.0 98.5 98.5 98.5 98.5 98.5 98.5 100
AMB 1.5 6.1 98.5 100
C. tropicalis (38) FLU 2.6 7.9 31.6 44.7 60.5 76.3 81.6 81.7 81.8 81.9 81.10 100




a 2.8 11.3 17.9 37.7 57.1 67.9 80.7 86.3 88.2 94.3 100
ITR
b 45.3 61.3 72.2 77.8 79.7 83.0 86.3 87.3 87.7 90.1 100
AMB 8.0 30.7 99.5 100
a FLU: fluconazole, ITR: itraconazole, AMB: amphotericin B;
b Fluconazole drug concentrations was evaluated from 0.125 to 64 μg/ml;
c Itraconazole and
amphotericin B drug concentrations were evaluated from 0.03 to 16 μg/ml;
d Values corresponding to MICs at which at least 50% of isolates are inhibited are
listed in underlined type and 90% in bold type;
e Included 2 C. lusitaniae (FLU 2.0, ITRA 0.06; AMB 1.0) and 1 C. pelliculosa (FLU 2.0, ITRA 0.25; AMB 0.5).
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high frequency of C. parapsilosis both in BSI and PF. C.
albicans continues to occur in an important number of
infection cases, with homogeneous distribution among
all the evaluated clinical sources. C. glabrata presents a
high proportion of resistant isolates, which reinforces
the necessity to carry out the correct species identifica-
tion in association with the susceptibility tests.
Methods
Origin of isolates
A total of 212 clinical isolates of Candida spp., isolated
from bloodstream infections - BSI (102 isolates), urinary
tract infections - UTI (85 isolates) and and peritoneal
fluid - PF (25 isolates), obtained from patients from
Clinical Hospital of the UNESP School of Medicine,
Botucatu, São Paulo State, between January 1998 and
January 2005 were evaluated in the study. The criteria
and/or condition for the selection of Candida isolates to
be analyzed were: i) the patients must be presenting
clinical evidence of infection; ii) the materials from
blood and peritoneal fluid were always collected by ster-
ile puncture; iii) the positive cultures both from blood
and peritoneal fluid were obtained in BACTEC System
(BD Microbiology, Cockeysville, MD), followed by plat-
ing culture and identification by microscopy, biochem-
ical tests and VITEK·ONE® (BioMérieux, Durham, NC);
iv) for the urine, the patients also must present clinical
evidence of infection, the materials were collected in
sterile cups from midstream urine specimen obtained
after cleansing the external urethral meatus, cultured in
MacConkey (Oxoid, Basingstoke, UK), Lactose Electro-
lyte Deficient agar (CLED; Oxoid,. Basingstoke, UK) and
Sabouraud dextrose (Oxoid, Basingstoke, UK) agar
plates, with counts equal to or above 10
4 colonies per
ml. The peritoneal fluid materials were collected from
patients in continuous ambulatory peritoneal dialysis
(CAPD) by sterile puncture and we did not include sam-
ples from drainage tubes or bags. Repetitive isolates
from the same patient were not included. All isolates
were stored, in vial tubes containing Brain Heart Infu-
sion plus 10% glycerol, in a freezer at -80°C. At the
moment of the study each isolate was cultured on
Sabouraud dextrose agar plates at 35°C.
Species identification
All Candida species isolates were re-identified based on
colony morphology on Chromogenic agar (CHROMagar
Candida, Difco), microscopy features on Corn-meal
agar slide culture, as well as the assimilation and fer-
mentation tests.
Susceptibility testing
Reference antifungal susceptibility testing of all 212 iso-
lates was performed by BMD (broth microdilution)
exactly as described in CLSI document M27-A2 [29]
against fluconazole (Pfizer, Sao Paulo, Brazil), itracona-
zole (Janssen, Beerse, Belgium) and amphotericin B
(Sigma, St. Louis, MO, USA). The isolates were incu-
bated at 35°C and the presence or absence of growth,
after 48 h, was observed by visual inspection. The MIC
endpoint for amphotericin B was considered the lowest
tested drug concentration able to prevent any visible
growth, while the MIC for azoles was considered the
lowest tested drug concentration causing a significant
reduction (approximately 50%) in growth compared to
the growth of the drug-free positive control [29]. MIC
interpretations follow the CLSI breakpoints [29] for flu-
conazol (≤8 ug/ml, susceptible; 16-32 ug/ml, SDD, ≥64,
resistant) and itraconazole (≤0.125 μg/ml, susceptible;
0.25-0.5 ug/ml, SDD, ≥1, resistant). For amphotericin B,
due to a lack of consensus about the definition of this
drug’sM I C ,p r e v i o u si n t e r p r e t a t i v eb r e a k p o i n t s
described elsewhere [30] were employed (≤1 ug/ml, sus-
ceptible, ≥2, resistant).
Quality control
QC was performed for BMD in accordance with CLSI
documents M27-A2 [29] by using Candida krusei
ATCC 6258 and Candida parapsilosis ATCC 22019.
List of abbreviations
BSI: bloodstream infection; UTI: urinary tract infection;
PF: peritoneal fluid; CAPD: continuous ambulatory peri-
toneal dialysis; BMD: Broth microdilution.
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